Drug Profile
IMC 3C5
Alternative Names: IMC-3C5; LY-3022856Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Vegenics
- Developer ImClone Systems
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Jul 2014 Eli Lilly completes a phase I trial in Solid tumours (late-stage disease, second-line therapy or greater) in the US (NCT01288989)
- 15 May 2013 IMC 3C5 is still in phase I trials for solid tumours (late-stage disease, second-line therapy or greater) in USA
- 06 Apr 2011 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)